Efficacy and Safety Profile of Cisatracurium Besylate for IAH

• Status: Not yet recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized, double-blinded, controlled design. In this study, Cisatracurium Besylate was selected for treatment in Intra-abdominal hypertension or abdominal compartment syndrome,accompanied with evaluating the effects on the duration of organ failure,length of hospital stay and mortality.To clarify the effect of Cisatracurium Besylate on IAH/ACS is of great significance to the clinical applications.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Nankai Hospital
• Treatments: Cisatracurium

Criteria

Inclusion Criteria:

1. Intra-abdominal pressure≥12mmHg

2. Age ≥18 years old

3. Obtain informed consent.

Exclusion Criteria:

1. Pregnancy pancreatitis

2. Patients who have undergone percutaneous puncture or surgical drainage before admission, and have undergone surgical decompression due to early abdominal hypertension

3. Patients with a history of chronic organ dysfunction (such as uremia, COPD, liver cirrhosis, heart failure, etc.)

4. Those who refuse to participate in the research